The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder.
Yohann Loriot
No relevant relationships to disclose
Karim Fizazi
Other Remuneration - Karim Fizazi
Joan Carles
No relevant relationships to disclose
Garry Alan Weems
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
Lacey Chance
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
Neeraj Agarwal
No relevant relationships to disclose